PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals Inc's account receivable for the three months ended in Sep. 2016 was $3.94 Mil. Progenics Pharmaceuticals Inc's revenue for the three months ended in Sep. 2016 was $53.85 Mil. Hence, Progenics Pharmaceuticals Inc's days sales outstanding for the three months ended in Sep. 2016 was 6.68.
During the past 13 years, Progenics Pharmaceuticals Inc's highest Days Sales Outstanding was 180.24. The lowest was 0.36. And the median was 32.86.
Progenics Pharmaceuticals Inc's days sales outstanding declined from Sep. 2015 (99.29) to Sep. 2016 (6.68).
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Account receivable can be measured by Days Sales Outstanding.
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as
Progenics Pharmaceuticals Inc's Days Sales Outstanding for the quarter that ended in Sep. 2016 is calculated as:
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Progenics Pharmaceuticals Inc Annual Data
Progenics Pharmaceuticals Inc Quarterly Data